Published in Postgrad Med J on May 01, 1981
Palliative care. BMJ (1994) 0.93
Dyspnoea in palliative care. BMJ (1992) 0.75
Respiratory depression caused by nitrazepam in patients with respiratory failure. Lancet (1971) 1.64
Respiratory acidosis. I. Effects of decreasing respiratory minute volume in patients with severe chronic pulmonary emphysema, with specific reference to oxygen, morphine and barbiturates. Am J Med (1954) 1.44
Effects of chlordiazepoxide in respiratory failure due to chronic bronchitis. Lancet (1974) 1.27
Effect of nitrazepam in chronic obstructive bronchitis. Br Med J (1972) 1.20
Carbon dioxide response lines in young adults: the limits of the normal response. Am Rev Respir Dis (1976) 1.10
Letter: The use of oral diazepam in patients with obstructive lung disease and hypercapnia. Ann Intern Med (1975) 0.88
Prolonged respiratory depression caused by drug combinations. Muscle relaxants and intraperitoneal antibiotics as etiologic agents. JAMA (1963) 0.87
Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA (2000) 8.06
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.89
Differences in hospital asthma management. Lancet (1988) 5.86
Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med (2001) 4.39
Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"? Br Med J (1977) 4.20
TB policy and the badger culling trials. Vet Rec (2006) 4.02
TB policy and the badger culling trials. Vet Rec (2006) 3.67
"Black blood" T2-weighted inversion-recovery MR imaging of the heart. Radiology (1996) 3.34
Bovine tuberculosis: towards a future control strategy. Vet Rec (2000) 3.27
Extracellular and intracellular polygllacturonic acid trans-eliminases of Erwinia carotovora. Arch Biochem Biophys (1968) 3.07
Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting. J Clin Microbiol (1996) 2.95
Postmarketing surveillance of the safety of cimetidine: 12 month mortality report. Br Med J (Clin Res Ed) (1983) 2.90
Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994. A report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Med J Aust (1996) 2.78
Analgesic nephropathy: clinical syndrome and prognosis. Br Med J (1971) 2.77
Management of asthma in hospital: a prospective audit. Br Med J (Clin Res Ed) (1988) 2.77
Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet (1994) 2.62
Post marketing surveillance of captopril (for hypertension): a preliminary report. Br J Clin Pharmacol (1987) 2.56
Non-prescription use of bronchodilator aerosols. Med J Aust (1992) 2.41
Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study. Br Med J (Clin Res Ed) (1982) 2.40
Lincomycins in the treatment of bacteroides infections. Br Med J (1972) 2.38
Human immunodeficiency virus and drug misuse: the Edinburgh experience. Br Med J (Clin Res Ed) (1987) 2.37
Attitudes of physicians and public to pharmaceutical industry 'gifts'. Intern Med J (2010) 2.20
Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia. Intern Med J (2006) 2.19
Intravenous contrast media: use and associated mortality. Med J Aust (1991) 2.18
Changes to the Pharmaceutical Benefits Advisory Committee. Med J Aust (2001) 2.14
Transferring evidence from research into practice: 1. The role of clinical care research evidence in clinical decisions. ACP J Club (1996) 2.10
Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism. Br Med J (1980) 2.09
Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. Q J Med (1985) 2.07
Mediastinal emphysema: aetiology, diagnosis, and treatment. Thorax (1966) 2.04
Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med (2000) 2.04
Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis (2001) 2.04
The yellow card: mark II. BMJ (1990) 2.00
Death from thyrotoxicosis. Lancet (1973) 1.93
The changing natural history of spinal muscular atrophy type 1. Neurology (2007) 1.87
Prostate cancer: comparison of transrectal US and digital rectal examination for screening. Radiology (1988) 1.83
Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up. Br Med J (Clin Res Ed) (1985) 1.78
Benzodiazepine drugs in general medical patients. Br Med J (1976) 1.74
An evaluation of the potential effects of ivermectin on the decomposition of cattle dung pats. Vet Rec (1993) 1.73
Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut (2000) 1.69
Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Med J Aust (1989) 1.68
Renin and acute renal failure: studies in man. Br Med J (1970) 1.66
Gonadal effects on food intake and adiposity: a metabolic hypothesis. Physiol Behav (1979) 1.65
Cimetidine and ranitidine in duodenal ulcer. Br Med J (1980) 1.63
Disodium chromoglycate in the treatment of allergic bronchial asthma. Lancet (1968) 1.61
Adverse reactions to potassium chloride. Q J Med (1974) 1.60
Detection of drug-induced disease. Br J Clin Pharmacol (1979) 1.56
Blood loss in the Kolff twin-coil artificial kidney. Nephron (1970) 1.50
The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention. 1. A meta-analysis of cholesterol-lowering trials. Med J Aust (1991) 1.47
Effect of furosemide on antibiotic-induced renal damage in rats. J Infect Dis (1972) 1.46
The metabolism of crotyl phosphate, crotyl alcohol and crotonaldehyde. Xenobiotica (1971) 1.44
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev (2002) 1.43
Veterinary Products Committee working group report on feline and canine vaccination. Vet Rec (2002) 1.42
Patients as a direct source of information on adverse drug reactions. BMJ (1988) 1.42
Systematic review and meta-analysis of the use of fibrin sealant to prevent seroma formation after breast cancer surgery. Br J Surg (2006) 1.41
Recent changes in the profile of prescription NSAID use in Australia. Med J Aust (2000) 1.41
Somatostatin in treatment of haematemesis and melaena. Lancet (1985) 1.39
Intensive hospital monitoring study of intravenous cimetidine. Arch Intern Med (1986) 1.38
Demographic characteristics of the equine population of northern Britain. Vet Rec (1999) 1.38
Glucomannan and risk of oesophageal obstruction. Br Med J (Clin Res Ed) (1986) 1.38
Disposition of oxytetracycline in pigs after i.m. administration of two long-acting formulations. J Vet Pharmacol Ther (2002) 1.38
HTLV-III antibodies in an Edinburgh clinic. Lancet (1986) 1.35
Cholestatic hepatitis associated with flucloxacillin. Med J Aust (1993) 1.34
Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol (2001) 1.33
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev (2000) 1.33
Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis (1981) 1.33
The importance of limited exposure to ultraviolet radiation and dietary factors in the aetiology of Asian rickets: a risk-factor model. Q J Med (1987) 1.32
Potassium supplements in patients receiving long-term diuretics for oedema. Q J Med (1976) 1.31
Microangiopathic haemolytic anaemia and the pathogenesis of malignant hypertension. Lancet (1969) 1.31
Oligogalacturonide trans-eliminase of Erwinia carotovora. Arch Biochem Biophys (1968) 1.31
Pathogenesis and diagnosis of infections with Mycobacterium bovis in cattle. Independent Scientific Group on Cattle TB. Vet Rec (2000) 1.27
Improving management of asthma: closing the loop or progressing along the audit spiral? Qual Health Care (1992) 1.27
Metabolic regulation of polygalacturonic acid trans-eliminase in Erwinia. Eur J Biochem (1969) 1.26
The [14C]-aminopyrine breath test. A comparison of different forms of analysis. Br J Clin Pharmacol (1979) 1.26
Record linkage study of hypokalaemia in hospitalized patients. Postgrad Med J (1986) 1.25
Hyponatraemia during carbamazepine treatment. Br Med J (1977) 1.25
Severe hypokalemia in hospitalized patients. Arch Intern Med (1979) 1.24
Measurement of blood PO2 with the microcathode electrode. J Appl Physiol (1966) 1.23
Adverse reactions to trimethoprim-sulfamethoxazole. Rev Infect Dis (1982) 1.23
Traumatic spinal extradural hematoma associated with cervical fractures in rheumatoid spondylitis. J Trauma (1973) 1.23
Herd-level risk factors associated with tuberculosis breakdowns among cattle herds in England before the 2001 foot-and-mouth disease epidemic. Biol Lett (2005) 1.23
Lyme borreliosis habitat assessment. Zentralbl Bakteriol (1998) 1.22
Continuous infusion of frusemide in refractory oedema. Br Med J (1978) 1.20
Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. Gut (1992) 1.20
Atracurium--a post-marketing surveillance study: methods and U.S. experience. Br J Anaesth (1989) 1.17
Alzheimer's disease in antacid users. Lancet (1989) 1.17
Protein-calorie undernutrition in hospitalized cancer patients. Am J Med (1980) 1.16
The nephrotoxicity of cephaloridine. Postgrad Med J (1970) 1.16
Metabolic approaches to cancer cachexia. Annu Rev Nutr (1982) 1.15
Gonadal influences on adiposity. Int J Obes (1985) 1.15
Adverse reactions to co-trimoxazole in hospitalized medical patients. Am J Med Sci (1978) 1.15
Hyperkalaemia in patients in hospital. Br Med J (Clin Res Ed) (1983) 1.13